---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-105942"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:40:58.652609+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences Q3 revenue $239.5M (+29% YoY); raises FY2025 guidance to $845-865M

## Summary
- Q3 net revenue $239.5M (WAKIX), +29% YoY; GAAP EPS $0.87, adjusted EPS $1.08.
- Raised 2025 revenue guidance to $845-865M from $820-860M.
- Record quarterly patient adds ~500, total ~8,100 average narcolepsy patients.
- Cash & investments $778M; generated $106M cash flow in Q3.
- Pipeline: pitolisant HD IND filed; Phase 3 narcolepsy/IH starts Q4; orexin-2 agonist first subject Q4.

## SEC filing metadata
- accession: 0001104659-25-105942
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000110465925105942/0001104659-25-105942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000110465925105942/hrmy-20251104x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-105942
- JSON: https://secwatch.observer/filing/0001104659-25-105942.json
- Plain text: https://secwatch.observer/filing/0001104659-25-105942.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.